AbCellera Biologics Inc. (ABCL) climbed to a new 52-week high of $5.97 on Wednesday, ending the regular session just below that mark at $5.96. Momentum continued after hours, with the stock rising another 11.58% to finish at $6.65, building on its earlier 18.49% gain. The move follows a series of recent developments that have drawn attention to the company's expanding immunology pipeline and clinical progress.
AbCellera, a biotechnology firm focused on antibody-based therapies, has been steadily advancing its portfolio, with several programs now entering human trials.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com